FDA to Remove Boxed Warning From Some Asthma Meds

The FDA will remove a Boxed Warning from certain inhaled medications used to treat asthma and chronic obstructive pulmonary disease (COPD).
Source: WebMD Health - Category: Consumer Health News Source Type: news

Related Links:

CONCLUSION: The results of our study may offer useful evidence for future development of female-specific prevention and public health intervention programs in aboriginal communities to reduce the burden of ACO. PMID: 31106621 [PubMed - as supplied by publisher]
Source: Journal of Asthma - Category: Respiratory Medicine Tags: J Asthma Source Type: research
This article describes 3 cases of IPA. Two patients had a history of chronic obstructive pulmonary disease (COPD) and asthma, and the other patient had no underlying diseases. The Aspergillus fumigatus gene was found in the bronchoalveolar lavage fluid in all three cases by NGS. This report explores the role of NGS in the diagnosis of IPA and emphasizes that IPA may occur in non-neutropenic patients. PMID: 31105860 [PubMed]
Source: American Journal of Translational Research - Category: Research Tags: Am J Transl Res Source Type: research
Publication date: Available online 19 May 2019Source: Life SciencesAuthor(s): Md. Samsuzzaman, Md. Sahab Uddin, Muhammad Ajmal Shah, Bijo MathewAbstractAirway mucin overproduction is the hallmark risk factor of asthma, which is associated with the reduction of lung function. An aberrant mucin expression is responsible for airway obstruction due to its high viscous characteristics. Among the mucins discovered, MUC5AC is the prime mucin of airway epithelia. Nowadays, mucins induced asthma and chronic obstructive pulmonary disease (COPD) are a great concern all over the world. This review focuses on the effects of natural com...
Source: Life Sciences - Category: Biology Source Type: research
The device is being trialled on NHS patients with asthma and chronic obstructive pulmonary disease (COPD), a group of lung conditions including emphysema and chronic bronchitis.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
CONCLUSIONS: In participants with chronic bronchitis or COPD, we are moderately confident that treatment with mucolytics leads to a small reduction in the likelihood of having an acute exacerbation, in days of disability per month and possibly hospitalisations, but is not associated with an increase in adverse events. There appears to be limited impact on lung function or health-related quality of life. Results are too imprecise to be certain whether or not there is an effect on mortality. Our confidence in the results is reduced by high levels of heterogeneity in many of the outcomes and the fact that effects on exacerbat...
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Tags: Cochrane Database Syst Rev Source Type: research
The consultation on proposed amendments and additions to the NICE indicators for asthma, COPD, heart failure, multi-morbidity, frailty, familial hypercholesterolaemia (HF), alcohol and HIV testing is still open.
Source: NHS Networks - Category: UK Health Source Type: news
AbstractSeveral factors have been associated with the development of asthma and asthma-related morbidity and mortality. Exposures in the environment such as allergens and air pollutants have traditionally been linked to the risk of asthma and asthma outcomes. More recent literature has identified chronic psychosocial stress as an additional environmental exposure to consider in relation to asthma. Adverse childhood events (ACEs) and chronic and toxic stress have been associated with chronic diseases such as cardiovascular disease, cancer, and chronic obstructive pulmonary disease. Chronic stress has also been shown to resu...
Source: Clinical Reviews in Allergy and Immunology - Category: Allergy & Immunology Source Type: research
Conclusions About 30% of patients with persistent airflow limitation were diagnosed with ACO. ACO patients had lower lung function and higher respiratory impedance compared with COPD patients. J. Med. Invest. 66 : 157-164, February, 2019. PMID: 31064931 [PubMed - in process]
Source: Journal of Medical Investigation - Category: General Medicine Tags: J Med Invest Source Type: research
Publication date: May–June 2019Source: The Journal of Allergy and Clinical Immunology: In Practice, Volume 7, Issue 5Author(s): Richard H. Stanford, Carlyne Averell, Emily D. Parker, Cori Blauer-Peterson, Tyler K. Reinsch, Ami R. BuikemaBackgroundAlthough efficacy and safety of fluticasone furoate/vilanterol (FF/VI) and budesonide/formoterol (BUD/F) have been demonstrated in clinical studies, real-world comparisons of utilization have not been performed.ObjectiveTo compare similar patients with asthma initiating FF/VI or BUD/F on measures of adherence, persistence, and the asthma medication ratio (AMR).MethodsThis wa...
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Publication date: May–June 2019Source: The Journal of Allergy and Clinical Immunology: In Practice, Volume 7, Issue 5Author(s): Ahmed Yousuf, Wadah Ibrahim, Neil J. Greening, Christopher E. BrightlingChronic obstructive pulmonary disease (COPD) is a significant cause of morbidity and mortality worldwide. In contrast to other chronic diseases, COPD is increasing in prevalence and is projected to be the third leading cause of death and disability worldwide by 2030. Recent advances in understanding the underlying pathophysiology of COPD has led to the development of novel targeted therapies (biologics and small molecule...
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
More News: Asthma | Chronic Obstructive Pulmonary | Health | Warnings